MMC vs SGMO · P/E 22, rev $24.46B vs rev $57.8M
Marsh & McLennan Companies Inc (MMC) versus Sangamo Therapeutics Inc (SGMO) — a side-by-side from cached financials, not a winner call.
Marsh & McLennan Companies Inc (MMC) is a insurance brokers company listed on US.
Sangamo Therapeutics Inc (SGMO) is a biotechnology company listed on NASDAQ.
Latest reported MMC revenue for 2024-12-31 was $24.46B. Net income was $4.12B. Revenue was up 7.6% from 2023-12-31 to 2024-12-31. MMC currently screens at market cap $89.82B and trailing P/E 21.9.
Latest reported SGMO revenue for 2024-12-31 was $57.8M. Net income was -$97.9M. Revenue was down 67.2% from 2023-12-31 to 2024-12-31. SGMO currently screens at market cap $74.6M.
MMC currently screens at market cap $89.82B and trailing P/E 21.9. SGMO currently screens at market cap $74.6M.
Not investment advice. Open the MMC and SGMO stock pages for the full models.
Not investment advice.